{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:33:27Z","timestamp":1790696007958,"version":"4.1.0"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T00:00:00Z","timestamp":1597708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["19-74-10022"],"award-info":[{"award-number":["19-74-10022"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002261","name":"Russian Foundation for Basic Research","doi-asserted-by":"publisher","award":["19-54-10005"],"award-info":[{"award-number":["19-54-10005"]}],"id":[{"id":"10.13039\/501100002261","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000266","name":"Engineering and Physical Sciences Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.01460","type":"journal-article","created":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T01:24:18Z","timestamp":1597713858000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":42,"title":["Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy"],"prefix":"10.3389","volume":"10","author":[{"given":"Vitaly","family":"Chasov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Mirgayazova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Zmievskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raniya","family":"Khadiullina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aygul","family":"Valiullina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Stephenson Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Rizvanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias G. J.","family":"Baud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Bulatov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.cell.2009.04.050","article-title":"Modes of p53 regulation","volume":"137","author":"Kruse","year":"2009","journal-title":"Cell."},{"key":"B2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1038\/sj.onc.1210291","article-title":"Structure\u2013function\u2013rescue: the diverse nature of common p53 cancer mutants","volume":"26","author":"Joerger","year":"2007","journal-title":"Oncogene."},{"key":"B4","doi-asserted-by":"publisher","first-page":"E10869","DOI":"10.1073\/pnas.1808314115","article-title":"p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression","volume":"115","author":"Amelio","year":"2018","journal-title":"PNAS."},{"key":"B5","doi-asserted-by":"publisher","first-page":"631","DOI":"10.4155\/fmc.15.13","article-title":"Small-molecule MDM2-p53 inhibitors: recent advances","volume":"7","author":"Zhang","year":"2015","journal-title":"Future Med Chem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fonc.2016.00007","article-title":"Clinical overview of MDM2\/X-targeted therapies","volume":"6","author":"Burgess","year":"2016","journal-title":"Front Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.1093\/emboj\/17.17.5001","article-title":"The alternative product from the human CDKN2A locus, p14: participates in a regulatory feedback loop with p53 and MDM2","volume":"17","author":"Stott","year":"1998","journal-title":"EMBO J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.14670\/HH-11-636","article-title":"MDM2 beyond cancer: podoptosis, development, inflammation, and tissue regeneration","volume":"30","author":"Ebrahim","year":"2015","journal-title":"Histol Histopathol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s12668-016-0233-x","article-title":"Ubiquitin-proteasome system: promising therapeutic targets in autoimmune and neurodegenerative diseases","volume":"6","author":"Bulatov","year":"2016","journal-title":"BioNanoSci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.imlet.2018.08.001","article-title":"Promising new therapeutic targets for regulation of inflammation and immunity: RING-type E3 ubiquitin ligases","volume":"202","author":"Bulatov","year":"2018","journal-title":"Immunol Lett."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.3390\/molecules25051211","article-title":"Recent small-molecule inhibitors of the p53-MDM2 protein-protein interaction","volume":"25","author":"Beloglazkina","year":"2020","journal-title":"Molecules."},{"key":"B12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3389\/fphar.2018.00450","article-title":"Small molecule modulators of RING-Type E3 ligases: MDM and cullin families as targets","volume":"9","author":"Bulatov","year":"2018","journal-title":"Front Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In vivo activation of the p53 pathway by small-molecule antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science."},{"key":"B14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.molcel.2006.01.020","article-title":"p53 ubiquitination: Mdm2 and beyond","volume":"21","author":"Brooks","year":"2006","journal-title":"Mol Cell."},{"key":"B15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41420-018-0120-z","article-title":"Isatin-Schiff base-copper (II) complex induces cell death in p53-positive tumors","volume":"4","author":"Bulatov","year":"2018","journal-title":"Cell Death Discov."},{"key":"B16","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1021\/acsmedchemlett.5b00011","article-title":"Discovery of novel isatin-based p53 inducers","volume":"6","author":"Davidovich","year":"2015","journal-title":"ACS Med Chem Lett."},{"key":"B17","doi-asserted-by":"publisher","first-page":"32232","DOI":"10.18632\/oncotarget.8572","article-title":"Avoiding drug resistance through extended drug target interfaces: a case for stapled peptides","volume":"7","author":"Wei","year":"2016","journal-title":"Oncotarget."},{"key":"B18","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/humu.23035","article-title":"TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data","volume":"37","author":"Bouaoun","year":"2016","journal-title":"Hum Mutat."},{"key":"B19","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1126\/science.8023157","article-title":"Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations","volume":"265","author":"Cho","year":"1994","journal-title":"Science."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1128\/MCB.21.5.1874-1887.2001","article-title":"A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain","volume":"21","author":"Gaiddon","year":"2001","journal-title":"Mol Cell Biol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/0092-8674(91)90384-B","article-title":"Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation","volume":"65","author":"Milner","year":"1991","journal-title":"Cell."},{"key":"B22","doi-asserted-by":"publisher","first-page":"a001107","DOI":"10.1101\/cshperspect.a001107","article-title":"Mutant p53 gain-of-function in cancer","volume":"2","author":"Oren","year":"2010","journal-title":"Cold Spring Harb Perspect Biol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41420-020-0251-x","article-title":"Context is everything: extrinsic signalling and gain-of-function p53 mutants","volume":"6","author":"Amelio","year":"2020","journal-title":"Cell Death Discov."},{"key":"B24","doi-asserted-by":"publisher","first-page":"6241","DOI":"10.3390\/ijms20246241","article-title":"Do mutations turn p53 into an oncogene?","volume":"20","author":"Pitolli","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"6682","DOI":"10.1074\/jbc.M412767200","article-title":"Hsp90 is essential for restoring cellular functions of temperature-sensitive p53 mutant protein but not for stabilization and activation of wild-type p53: implications for cancer therapy","volume":"280","author":"M\u00fcller","year":"2005","journal-title":"J Biol Chem."},{"key":"B26","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/carcin\/bgl132","article-title":"Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers","volume":"28","author":"Dearth","year":"2007","journal-title":"Carcinogenesis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1093\/emboj\/17.7.1847","article-title":"Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations","volume":"17","author":"Brachmann","year":"1998","journal-title":"EMBO J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"16030","DOI":"10.1074\/jbc.M500179200","article-title":"Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations","volume":"280","author":"Joerger","year":"2005","journal-title":"J Biol Chem."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1016\/j.febslet.2014.04.017","article-title":"Mutant p53 reactivation by small molecules makes its way to the clinic","volume":"588","author":"Bykov","year":"2014","journal-title":"FEBS Lett."},{"key":"B30","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3390\/cancers9120172","article-title":"PRIMA-1 and PRIMA-1Met (APR-246): from mutant\/wild type p53 reactivation to unexpected mechanisms underlying their potent anti-tumor effect in combinatorial therapies","volume":"9","author":"Perdrix","year":"2017","journal-title":"Cancers."},{"key":"B31","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ccr.2009.03.003","article-title":"PRIMA-1 reactivates mutant p53 by covalent binding to the core domain","volume":"15","author":"Lambert","year":"2009","journal-title":"Cancer Cell."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1182\/blood-2014-01-548800","article-title":"PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH\/ROS balance","volume":"124","author":"Tessoulin","year":"2014","journal-title":"Blood."},{"key":"B33","doi-asserted-by":"publisher","first-page":"E5271","DOI":"10.1073\/pnas.1610421113","article-title":"2-Sulfonylpyrimidines: mild alkylating agents with anticancer activity toward p53-compromised cells","volume":"113","author":"Bauer","year":"2016","journal-title":"PNAS."},{"key":"B34","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/humu.20495","article-title":"Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database","volume":"28","author":"Petitjean","year":"2007","journal-title":"Hum Mutat."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/sj.onc.1203434","article-title":"Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy","volume":"19","author":"Bullock","year":"2000","journal-title":"Oncogene."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.4155\/fmc-2019-0181","article-title":"A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C","volume":"11","author":"Bauer","year":"2019","journal-title":"Future Med Chem."},{"key":"B37","doi-asserted-by":"publisher","first-page":"6034","DOI":"10.1093\/nar\/gkt305","article-title":"Small molecule induced reactivation of mutant p53 in cancer cells","volume":"41","author":"Liu","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ejmech.2018.04.035","article-title":"Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines","volume":"152","author":"Baud","year":"2018","journal-title":"Eur J Med Chem."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/j.drudis.2015.07.006","article-title":"Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer","volume":"20","author":"Blanden","year":"2015","journal-title":"Drug Discov Today."},{"key":"B40","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1039\/c003915b","article-title":"The missing zinc: p53 misfolding and cancer","volume":"2","author":"Loh","year":"2010","journal-title":"Metallomics."},{"key":"B41","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.ccr.2012.03.042","article-title":"Allele-specific p53 mutant reactivation","volume":"21","author":"Yu","year":"2012","journal-title":"Cancer Cell."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.4161\/cc.10.10.15642","article-title":"Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs","volume":"10","author":"Puca","year":"2011","journal-title":"Cell Cycle."},{"key":"B43","doi-asserted-by":"publisher","first-page":"5650","DOI":"10.1158\/1078-0432.CCR-19-0096","article-title":"COTI-2, a novel thiosemicarbazone derivative, exhibits antitumor activity in HNSCC through p53-dependent and -independent mechanisms","volume":"25","author":"Lindemann","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1089\/ars.2017.7487","article-title":"Anticancer thiosemicarbazones: chemical properties, interaction with iron metabolism, and resistance development","volume":"30","author":"Heffeter","year":"2019","journal-title":"Antioxid Redox Signal."},{"key":"B45","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3390\/nano9010105","article-title":"Vectors for Glioblastoma Gene Therapy: Viral & Non-Viral Delivery Strategies","volume":"9","author":"Caffery","year":"2019","journal-title":"Nanomaterials (Basel)."},{"key":"B46","doi-asserted-by":"publisher","first-page":"759","DOI":"10.2217\/14796694.4.6.759","article-title":"Potential of Advexin: a p53 gene-replacement therapy in Li-Fraumeni syndrome","volume":"4","author":"Nemunaitis","year":"2008","journal-title":"Future Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1089\/hum.2017.218","article-title":"The first approved gene therapy product for cancer Ad-p53 (Gendicine): 12 years in the clinic","volume":"29","author":"Zhang","year":"2018","journal-title":"Hum Gene Ther."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1080\/15384047.2016.1235655","article-title":"Autoregulated expression of p53 from an adenoviral vector confers superior tumor inhibition in a model of prostate carcinoma gene therapy","volume":"17","author":"Tamura","year":"2016","journal-title":"Cancer Biol Ther."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1073\/pnas.93.3.1156","article-title":"Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain","volume":"93","author":"Kim","year":"1996","journal-title":"Proc Natl Acad Sci."},{"key":"B50","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/nrg2842","article-title":"Genome editing with engineered zinc finger nucleases","volume":"11","author":"Urnov","year":"2010","journal-title":"Nat Rev Genet."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1126\/science.1178811","article-title":"Breaking the code of DNA binding specificity of TAL-type III effectors","volume":"326","author":"Boch","year":"2009","journal-title":"Science."},{"key":"B52","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrm3486","article-title":"TALENs: a widely applicable technology for targeted genome editing","volume":"14","author":"Joung","year":"2013","journal-title":"Nat Rev Mol Cell Biol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","article-title":"CRISPR-Cas9 structures and mechanisms","volume":"46","author":"Jiang","year":"2017","journal-title":"Annu Rev Biophys."},{"key":"B54","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature."},{"key":"B55","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature."},{"key":"B56","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature."},{"key":"B57","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.tibtech.2018.01.014","article-title":"Restoring the p53 \u201cGuardian\u201d phenotype in p53-deficient tumor cells with CRISPR\/Cas9","volume":"36","author":"Chira","year":"2018","journal-title":"Trends Biotechnol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"e0120396","DOI":"10.1371\/journal.pone.0120396","article-title":"Large genomic fragment deletions and insertions in mouse using CRISPR\/Cas9","volume":"10","author":"Zhang","year":"2015","journal-title":"PLoS One."},{"key":"B59","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3390\/genes11060704","article-title":"Therapeutic editing of the TP53 gene: is CRISPR\/Cas9 an option?","volume":"11","author":"Mirgayazova","year":"2020","journal-title":"Genes."},{"key":"B60","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1021\/acschembio.7b00680","article-title":"The promise and challenge of in vivo delivery for genome therapeutics","volume":"13","author":"Wilson","year":"2018","journal-title":"ACS Chem Biol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/s41591-018-0050-6","article-title":"p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells","volume":"24","author":"Ihry","year":"2018","journal-title":"Nat Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41591-018-0049-z","article-title":"CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response","volume":"24","author":"Haapaniemi","year":"2018","journal-title":"Nat Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.humpath.2019.02.006","article-title":"TP53 missense mutation is associated with increased tumor-infiltrating T-cells in primary prostate Cancer","volume":"87","author":"Kaur","year":"2019","journal-title":"Hum Pathol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.237453","article-title":"p53, cancer and the immune response","volume":"133","author":"Blagih","year":"2020","journal-title":"J Cell Sci."},{"key":"B65","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.3390\/ijms21103452","article-title":"P53: a guardian of immunity becomes its saboteur through mutation","volume":"21","author":"Agupitan","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B66","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3390\/cancers12010125","article-title":"Advancing CAR T-cell therapy for solid tumors: lessons learned from lymphoma treatment","volume":"12","author":"Titov","year":"2020","journal-title":"Cancers."},{"key":"B67","doi-asserted-by":"publisher","first-page":"5099","DOI":"10.1200\/JCO.2005.03.158","article-title":"Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome","volume":"23","author":"Carbone","year":"2005","journal-title":"J Clin Oncol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1002\/ijc.22584","article-title":"Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck","volume":"120","author":"Ito","year":"2007","journal-title":"Int J Cancer."},{"key":"B69","doi-asserted-by":"publisher","first-page":"7199","DOI":"10.1158\/1078-0432.CCR-07-0682","article-title":"Alteration of cellular and humoral immunity by mutant p53 protein and processed mutant peptide in head and neck cancer","volume":"13","author":"Couch","year":"2007","journal-title":"Clin Cancer Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"eaao5931","DOI":"10.1126\/scitranslmed.aao5931","article-title":"Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer","volume":"10","author":"Tanyi","year":"2018","journal-title":"Sci Transl Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/mt.2016.51","article-title":"Stable, nonviral expression of mutated tumor neoantigen-specific T-cell receptors using the sleeping beauty Transposon\/Transposase system","volume":"24","author":"Deniger","year":"2016","journal-title":"Mol Ther."},{"key":"B72","doi-asserted-by":"publisher","first-page":"5562","DOI":"10.1158\/1078-0432.CCR-18-0573","article-title":"T-cell responses to TP53 \u201cHotspot\u201d mutations and unique neoantigens expressed by human ovarian cancers","volume":"24","author":"Deniger","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B73","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1158\/2326-6066.CIR-18-0686","article-title":"Immunologic recognition of a shared p53 mutated neoantigen in a patient with metastatic colorectal cancer","volume":"7","author":"Lo","year":"2019","journal-title":"Cancer Immunol Res."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1172\/JCI123791","article-title":"Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers","volume":"129","author":"Malekzadeh","year":"2019","journal-title":"J Clin Invest."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1158\/1078-0432.CCR-19-1874","article-title":"Antigen experienced T cells from peripheral blood recognize p53 neoantigens","volume":"26","author":"Malekzadeh","year":"2020","journal-title":"Clin Cancer Res."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.01460\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T01:24:23Z","timestamp":1597713863000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.01460\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,18]]},"references-count":75,"alternative-id":["10.3389\/fonc.2020.01460"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.01460","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,18]]},"article-number":"1460"}}